financetom
Business
financetom
/
Business
/
Nucor Expects Q4 Earnings to Fall to $0.55 to $0.65 a Share
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nucor Expects Q4 Earnings to Fall to $0.55 to $0.65 a Share
Dec 16, 2024 3:09 PM

05:48 PM EST, 12/16/2024 (MT Newswires) -- Nucor ( NUE ) said late Monday that Q4 earnings will likely be $0.55 to $0.65 per diluted share, down from $3.16 a year earlier, on "decreased earnings of the steel mills segment caused by decreased volumes and lower average selling prices."

Analysts polled by Factset expect $0.89.

Nucor ( NUE ) reported Q3 net earnings of $1.05 a share on Oct. 21 and forecast Q4 earnings would drop sequentially.

Shares of the company fell 1.1% in after-hours activity.

Price: 122.75, Change: -1.41, Percent Change: -1.14

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lennox International to Acquire HVAC Division of NSI Industries for $550 Million
Lennox International to Acquire HVAC Division of NSI Industries for $550 Million
Aug 18, 2025
08:32 AM EDT, 08/18/2025 (MT Newswires) -- Lennox International ( LII ) said Monday it has agreed to acquire the HVAC division of NSI Industries from Sentinel Capital Partners for $550 million. The acquisition includes well-known brands such as Duro Dyne and Supco, which produce essential HVAC components and technician-focused parts, the company said. The deal, expected to close in...
Catheter Precision Receives UK Approval for Suture Retention Device
Catheter Precision Receives UK Approval for Suture Retention Device
Aug 18, 2025
08:24 AM EDT, 08/18/2025 (MT Newswires) -- Catheter Precision ( VTAK ) said Monday that it has received registration and approval in the UK for its LockeT suture retention device, allowing it to launch sales in the nation. Catheter Precision ( VTAK ) said it has entered into an agreement with UK-based HC21 to distribute LockeT. LockeT received a CE...
Enlivex Therapeutics Says Allocetra Showed Improvements in Phase IIa Trial for Osteoarthritis
Enlivex Therapeutics Says Allocetra Showed Improvements in Phase IIa Trial for Osteoarthritis
Aug 18, 2025
08:25 AM EDT, 08/18/2025 (MT Newswires) -- Enlivex Therapeutics ( ENLV ) shares were up over 11% premarket Monday after the company said its Allocetra cell therapy demonstrated improvements in a phase IIa trial in patients with moderate-to-severe knee osteoarthritis. The Allocetra treatment arm showed a 24% reduction in knee pain and a 26% improvement in knee function compared with...
Opus Genetics Says FDA Approved Investigational New Drug Application for Retinal Diseases Drug Candidate
Opus Genetics Says FDA Approved Investigational New Drug Application for Retinal Diseases Drug Candidate
Aug 18, 2025
08:28 AM EDT, 08/18/2025 (MT Newswires) -- Opus Genetics ( IRD ) said Monday that the Investigational New Drug application for its OPGx-BEST1 gene therapy to treat bestrophin-1-related inherited retinal diseases was approved by the US Food and Drug Administration Following the approval, the company said it intends to start a phase 1/2 clinical trial in H2 2025 to evaluate...
Copyright 2023-2026 - www.financetom.com All Rights Reserved